Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Colorcon
McKesson
Medtronic
Baxter

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,382,327

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,382,327
Title:Anti-CD20 antibodies and methods of use
Abstract: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
Inventor(s): Smith; Ernest S. (Rochester, NY), Fisher, Jr.; Terrence L. (Rochester, NY)
Assignee: VACCINEX, INC. (Rochester, NY)
Application Number:11/869,170
Patent Claims:1. An immunoglobulin that specifically binds CD20, wherein said immunoglobulin comprises an immunoglobulin heavy chain comprising a variable heavy (V.sub.H) domain and an immunoglobulin light chain comprising a variable light (V.sub.L) domain, wherein said immunoglobulin is selected from the group consisting of: a) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:12 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; b) an immunoglobulin comprising the V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:13 and a V.sub.Ldomain comprising the amino acid sequence set forth in SEQ ID NO:10; c) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:14 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; d an immunoglobulin com risin a V domain comprising the amino acid sequence set forth in SEQ ID NO:15 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; e) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:16 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; f) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:17 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:10; g) an immunoglobulin com risin a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:18 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:10; h) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:13 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:11; and i) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:16 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:11.

2. The immunoglobulin of claim 1, wherein said immunoglobulin is an IgG1 kappa immunoglobulin.

3. The immunoglobulin of claim 2, wherein said IgG1 kappa immunoglobulin comprises a human IgG1 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin.

4. The immunoglobulin of claim 1, wherein said immunoglobulin exhibits increased complement-dependent cytotoxicity (CDC) as compared to rituximab.

5. The immunoglobulin of claim 1, further comprising a heterologous polypeptide fused thereto.

6. The immunoglobulin of claim 1, wherein said immunoglobulin is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.

7. A composition comprising the immunoglobulin of claim 1.

8. The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

9. The immunoglobulin of claim 1, wherein said V.sub.H domain comprises the amino acid sequence set forth in SEQ ID NO:16 and said V.sub.L domain comprises the amino acid sequence set forth in SEQ ID NO:10.

Details for Patent 9,382,327

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2026-10-10
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Free Forever Trial 2026-10-10
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Free Forever Trial 2026-10-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
Harvard Business School
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.